By contrast, Vioxx made $2.5 billion for Merck last year.
"He did so voluntarily," the agency said.
With Vioxx, researchers had been warning about the drug's possible cardiovascular risks since 2000, only a year after it was approved by the FDA.
``I was stunned,'' said Kim who had expected positive results.
The company was already facing two class action lawsuits alleging patient harm from Vioxx.
``I thought the risk was going to be larger than it was,'' he said.
``This morning Merck is announcing a voluntary worldwide withdrawal of Vioxx,'' Gilmartin began.
The FDA's own study of the Vioxx safety issue has become mired in controversy.
